CR9257A - Polimorfo cci-779 y uso del mismo - Google Patents

Polimorfo cci-779 y uso del mismo

Info

Publication number
CR9257A
CR9257A CR9257A CR9257A CR9257A CR 9257 A CR9257 A CR 9257A CR 9257 A CR9257 A CR 9257A CR 9257 A CR9257 A CR 9257A CR 9257 A CR9257 A CR 9257A
Authority
CR
Costa Rica
Prior art keywords
cci
polymorph
provides
preparing
pharmaceutical compositions
Prior art date
Application number
CR9257A
Other languages
English (en)
Inventor
Subodh S Deshmukh
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9257A publication Critical patent/CR9257A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion proporciona el polimorfo forma II de CCI-779; esta invencion tambien proporciona procedimientos para preparar el polimorfo forma II de CCI-779 y composiciones farmaceuticas que incluyen el polimorfo forma II de CCI-779.
CR9257A 2005-02-09 2007-07-18 Polimorfo cci-779 y uso del mismo CR9257A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65137405P 2005-02-09 2005-02-09

Publications (1)

Publication Number Publication Date
CR9257A true CR9257A (es) 2007-11-23

Family

ID=36570939

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9257A CR9257A (es) 2005-02-09 2007-07-18 Polimorfo cci-779 y uso del mismo

Country Status (19)

Country Link
US (1) US7442707B2 (es)
EP (1) EP1856130A1 (es)
JP (1) JP2008530090A (es)
KR (1) KR20070107030A (es)
CN (1) CN101115759A (es)
AR (1) AR052479A1 (es)
AU (1) AU2006213061A1 (es)
BR (1) BRPI0607932A2 (es)
CA (1) CA2595766A1 (es)
CR (1) CR9257A (es)
GT (1) GT200600044A (es)
IL (1) IL184560A0 (es)
MX (1) MX2007009590A (es)
NO (1) NO20073725L (es)
PE (1) PE20060996A1 (es)
RU (1) RU2007129264A (es)
TW (1) TW200638932A (es)
WO (1) WO2006086172A1 (es)
ZA (1) ZA200706628B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
WO2007067566A2 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
CN101321770A (zh) * 2005-12-07 2008-12-10 惠氏公司 由雷帕霉素42-酯硼酸酯制备雷帕霉素42-酯的可放大方法
AR058282A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
CN102282457A (zh) * 2009-01-21 2011-12-14 拜康有限公司 确定西罗莫司稳定性的方法和制备其稳定形式的工艺
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
DK1419154T3 (da) 2001-08-22 2006-01-09 Wyeth Corp Rapamycin-29-enoler
EP1419153A1 (en) 2001-08-22 2004-05-19 Wyeth Rapamycin dialdehydes
EP1646635A1 (en) 2003-07-16 2006-04-19 Wyeth Cci-779 isomer c
JP4227649B2 (ja) 2003-08-07 2009-02-18 ワイス Ｃｃｉ−７７９の位置選択的合成
UA84881C2 (ru) 2003-09-03 2008-12-10 Уайт Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
JP4224115B2 (ja) 2004-04-14 2009-02-12 ワイス ラパマイシン４２−エステル誘導体の位置特異的合成

Also Published As

Publication number Publication date
PE20060996A1 (es) 2006-11-13
KR20070107030A (ko) 2007-11-06
NO20073725L (no) 2007-09-05
CN101115759A (zh) 2008-01-30
GT200600044A (es) 2006-11-09
MX2007009590A (es) 2007-09-12
US20060178392A1 (en) 2006-08-10
IL184560A0 (en) 2007-10-31
EP1856130A1 (en) 2007-11-21
ZA200706628B (en) 2010-01-27
BRPI0607932A2 (pt) 2016-11-08
RU2007129264A (ru) 2009-03-20
US7442707B2 (en) 2008-10-28
JP2008530090A (ja) 2008-08-07
WO2006086172A1 (en) 2006-08-17
CA2595766A1 (en) 2006-08-17
AR052479A1 (es) 2007-03-21
TW200638932A (en) 2006-11-16
AU2006213061A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
CR8929A (es) Polimorfo ii de rapamicina y usos del mismo
CL2007002733A1 (es) Compuestos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de obtencion de los compuestos; composicion farmaceutica; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, osteoporosis y cancer.
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ATE528989T1 (de) Kristalline feste rasagilin-base
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CR9257A (es) Polimorfo cci-779 y uso del mismo
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
PA8693101A1 (es) Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
PA8778601A1 (es) Inhibidores de la unión entre hdm2 y el proteasoma
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR11861A (es) Compuestos organicos
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)